COPD (Chronic Obstructive Pulmonary Disease)

Respiratory
2
Pipeline Programs
5
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
1
Inhaled TreprostinilPhase 21 trial
Active Trials
NCT07037836Recruiting10Est. Jul 2027
Alliance Pharmaceuticals
1 program
1
Psilocybin therapyPhase 21 trial
Active Trials
NCT06782724Not Yet Recruiting108Est. Jan 2028
Viz.ai
Viz.aiCA - San Francisco
1 program
COPD Exacerbation Follow UpN/A1 trial
Active Trials
NCT07118306Not Yet Recruiting485Est. Dec 2026
Sanofi
SanofiPARIS, France
1 program
COPD Exacerbation Follow UpN/A
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Study That Will Evaluate the Brazilian Population With COPD.N/A1 trial
Active Trials
NCT06780046Recruiting693Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
United TherapeuticsInhaled Treprostinil
Alliance PharmaceuticalsPsilocybin therapy
Viz.aiCOPD Exacerbation Follow Up
AstraZenecaStudy That Will Evaluate the Brazilian Population With COPD.

Clinical Trials (4)

Total enrollment: 1,296 patients across 4 trials

NCT07037836United TherapeuticsInhaled Treprostinil

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

Start: Sep 2025Est. completion: Jul 202710 patients
Phase 2Recruiting
NCT06782724Alliance PharmaceuticalsPsilocybin therapy

Psilocybin Therapy for Psychological Distress in Palliative Patients

Start: Mar 2025Est. completion: Jan 2028108 patients
Phase 2Not Yet Recruiting
NCT07118306Viz.aiCOPD Exacerbation Follow Up

COPD Exacerbation Follow Up

Start: Oct 2025Est. completion: Dec 2026485 patients
N/ANot Yet Recruiting
NCT06780046AstraZenecaStudy That Will Evaluate the Brazilian Population With COPD.

Study That Will Evaluate the Brazilian Population With COPD.

Start: Jan 2025Est. completion: Sep 2027693 patients
N/ARecruiting

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,296 patients
5 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)